Fresh Tracks Therapeutics Inc Quick Ratio (FRTX) starting from the fourth quarter 2023 to fourth quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Fresh Tracks Therapeutics Inc   (FRTX)

Fresh Tracks Therapeutics Inc 's Quick Ratio

FRTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Fresh Tracks Therapeutics Inc 's Cash & cash equivalent, this led to improvement in Fresh Tracks Therapeutics Inc 's Quick Ratio to 6.56, Quick Ratio remained below Fresh Tracks Therapeutics Inc average.

Within Biotechnology & Pharmaceuticals industry 50 other companies have achieved higher Quick Ratio than Fresh Tracks Therapeutics Inc in fourth quarter 2023. While Quick Ratio total ranking has improved so far during the Q4 2023 to 463, from total ranking in the third quarter 2023 at 547.

Explain Quick Ratio?
How much Cash & cash equivalents FRTX´s has?
What are FRTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

FRTX Quick Ratio (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4
Y / Y Current Liabilities Change -45.31 % -34.25 % -35.39 % -55.78 % -36.13 %
Y / Y Cash & cash equivalent Change 25.21 % 6.84 % -38.2 % -37.74 % -67.71 %
Quick Ratio MRQ 6.56 5.7 4.89 5.19 2.87
FRTX's Total Ranking # 463 # 547 # 592 # 661 # 982
Seq. Current Liabilities Change -21.44 % 15.13 % -11.67 % -31.54 % -5.55 %
Seq. Cash & cash equivalent Change -9.58 % 34.33 % -16.87 % 24.01 % -22.84 %



Quick Ratio fourth quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 51
Healthcare Sector # 228
Overall Market # 463


Quick Ratio Statistics
High Average Low
36 9.23 1.01
(Jun 30 2019)   (Mar 31 2020)




Financial Statements
Fresh Tracks Therapeutics Inc 's Current Liabilities $ 2 Millions Visit FRTX's Balance sheet
Fresh Tracks Therapeutics Inc 's Cash & cash equivalent $ 11 Millions Visit FRTX's Balance sheet
Source of FRTX's Sales Visit FRTX's Sales by Geography


Cumulative Fresh Tracks Therapeutics Inc 's Quick Ratio

FRTX's Quick Ratio for the trailling 12 Months

FRTX Quick Ratio

 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth -44.26 % -41.56 % -38.22 % -44.87 % -44.65 %
Y / Y Cash & cash equivalent TTM Growth -17.6 % -42.19 % -50.47 % -49.79 % -51.89 %
Quick Ratio TTM 5.56 4.47 3.91 4.05 3.76
Total Ranking TTM # 2966 # 398 # 508 # 2584 # 789
Seq. Current Liabilities TTM Growth -15.18 % -10.83 % -9 % -19.01 % -11.07 %
Seq. Cash & cash equivalent TTM Growth 5.41 % 1.94 % -12.25 % -12.62 % -26.04 %

Quick ratio ranking by company, industry and sector >> Back to FRTX Financial Strength Comparisons >> Go to Compare FRTX Quick Ratio to its Competitors

On the trailing twelve months basis FRTX Cash & cash equivalent grew by 25.21 % in Q4 2023 year on year, while Current Liabilities faded to $2 millions, this led to increase in in Fresh Tracks Therapeutics Inc 's Quick Ratio to 5.56, Quick Ratio remained below FRTX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 94 other companies have achieved higher Quick Ratio than Fresh Tracks Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2023 from 398 to 2966.

Explain Quick Ratio?
How much Cash & cash equivalents FRTX´s has?
What are FRTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 95
Healthcare Sector # 675
Within the Market # 2966


trailing twelve months Quick Ratio Statistics
High Average Low
17.22 7.49 1.87
(Jun 30 2019)   (Sep 30 2020)




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Biotechnology & Pharmaceuticals Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Cullinan Therapeutics Inc   17.50 $ 467.067  Millions$ 26.697  Millions
Replimune Group Inc   17.25 $ 583.386  Millions$ 33.825  Millions
Lexeo Therapeutics Inc   16.61 $ 121.466  Millions$ 7.315  Millions
Krystal Biotech Inc   16.08 $ 532.178  Millions$ 33.094  Millions
Crispr Therapeutics Ag  15.57 $ 1,693.692  Millions$ 108.791  Millions
Prokidney Corp   15.56 $ 362.950  Millions$ 23.331  Millions
Engene Therapeutics Inc   15.51 $ 81.521  Millions$ 5.257  Millions
Cabaletta Bio Inc   15.08 $ 241.249  Millions$ 15.994  Millions
Anavex Life Sciences Corp   13.00 $ 151.024  Millions$ 11.617  Millions
Cg Oncology Inc   12.78 $ 187.674  Millions$ 14.685  Millions
Vaxcyte Inc   12.64 $ 1,080.227  Millions$ 85.458  Millions
Imagenebio Inc   12.35 $ 175.465  Millions$ 14.205  Millions
Allogene Therapeutics Inc   12.10 $ 448.697  Millions$ 37.079  Millions
Vor Biopharma Inc   11.68 $ 137.175  Millions$ 11.742  Millions
Scholar Rock Holding Corp  11.05 $ 279.938  Millions$ 25.333  Millions
Genenta Science S p a   10.82 $ 21.029  Millions$ 1.944  Millions
Voyager Therapeutics Inc   10.68 $ 230.875  Millions$ 21.627  Millions
Jasper Therapeutics Inc   10.42 $ 86.887  Millions$ 8.336  Millions
Caribou Biosciences Inc   10.15 $ 328.827  Millions$ 32.395  Millions
Vigil Neuroscience Inc   10.11 $ 117.940  Millions$ 11.661  Millions
Hillevax Inc   10.04 $ 303.483  Millions$ 30.225  Millions
Denali Therapeutics Inc   9.93 $ 1,034.511  Millions$ 104.157  Millions
Creative Medical Technology Holdings Inc   9.71 $ 3.467  Millions$ 0.357  Millions
Cardiff Oncology Inc   9.69 $ 101.132  Millions$ 10.440  Millions
Century Therapeutics inc   9.68 $ 172.738  Millions$ 17.846  Millions
4d Molecular Therapeutics Inc   9.34 $ 288.232  Millions$ 30.853  Millions
Achilles Therapeutics Plc  9.09 $ 131.539  Millions$ 14.472  Millions
Kymera Therapeutics Inc   9.04 $ 374.881  Millions$ 41.463  Millions
Silexion Therapeutics Corp  8.78 $ 4.620  Millions$ 0.526  Millions
Iteos Therapeutics Inc   8.75 $ 531.916  Millions$ 60.785  Millions

Date modified: 2026-06-22T14:32:37+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.